Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DCAF15 | Q66K64 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845376 | 0.90 | SMN1; SMN2 (0.47) | BACE1ALDH1A1RAB9APOLB | |
| SCHEMBL5845179 | 0.79 | NPC1 (0.57) | BACE1RAB9A | |
| SCHEMBL8280838 | 0.73 | BACE1 (0.94) | BACE1ALDH1A1RAB9AHSD11B1NR1I2 | |
| SCHEMBL5844634 | 0.71 | ALOX5AP (0.55) | HSD11B1DCAF15 | |
| SCHEMBL8280835 | 0.71 | BACE1 (1.00) | BACE1ALDH1A1RAB9AHSD11B1HSD11B2 | |
| SCHEMBL14433407 | 0.70 | BACE1 (0.97) | BACE1ALDH1A1RAB9AHSD11B1NR1I2 | |
| SCHEMBL5846112 | 0.69 | BACE1 (0.49) | BACE1ALDH1A1HSD11B1NR1I2HSD11B2 | |
| SCHEMBL5845190 | 0.67 | BACE1 (0.44) | BACE1HSD11B1NR1I2DCAF15 | |
| SCHEMBL31210280 | 0.67 | OPRM1 (0.59) | ALDH1A1HSD11B1HSD11B2POLB | |
| SCHEMBL31210281 | 0.67 | OPRM1 (0.59) | ALDH1A1HSD11B1HSD11B2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087623-B2 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040235913-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | CUNY GREGORY D (US) | 2004-11-25 | — | — | US | disclosed |
| US-6699866-B2 | FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS | SEPRACOR INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002083863-A2 | THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF | SEPRACOR, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235913-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | BACE1 358/4885ALDH1A1 755/4885RAB9A 694/4885 |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | BACE1 358/4885ALDH1A1 755/4885RAB9A 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.